This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	Isocitrate dehydrogenase 2 (IDH2)	<p>Patient sample and <i>in vitro</i> studies suggest mutant-selective IDH2 inhibitors could help treat patients with IDH2-mutant AML. In <i>in vitro</i> assays, AGI-6780 inhibited mutant IDH2 with nanomolar potency and selectivity over the wild-type enzyme. In primary human AML cells with mutant IDH2, AGI-6780 decreased levels of the (<i>R</i>)-enantiomer of 2-hydroxyglutarate (2-HG), an oncometabolite produced specifically by the mutant enzyme, and increased leukemic cell differentiation compared with vehicle. Next steps include further preclinical development of mutant IDH2 inhibitors in preparation for clinical trials in patients who have IDH2-mutant AML.</p> <p>Agios Pharmaceuticals Inc. has preclinical programs targeting IDH1 and IDH2 in cancers with mutations in the metabolic enzymes.</p> <p>SciBX 6(14); doi:10.1038/scibx.2013.330 Published online April 11, 2013</p>	Patent applications filed; partnered with Celgene Corp.	<p>Wang, F. <i>et al. Science</i>; published online April 4, 2013; doi:10.1126/science.1234769 Contact: Katharine E. Yen, Agios Pharmaceuticals Inc., Cambridge, Mass. e-mail: katharine.yen@agios.com</p>